Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PREP | P48147 | 4/20 | 0.45 |
| ▸ | CA12 | O43570 | 4/20 | 0.35 |
| ▸ | CA1 | P00915 | 4/20 | 0.35 |
| ▸ | CA9 | Q16790 | 4/20 | 0.35 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.33 |
| ▸ | MLYCD | O95822 | 1/20 | 0.32 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | TP53 | P04637 | 1/20 | 0.30 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21107473 | 0.79 | PREP (0.42) | PREPCA12CA1CA9MEN1 | |
| SCHEMBL22496040 | 0.79 | PREP (0.45) | PREPCA12CA1CA9MEN1 | |
| SCHEMBL22496064 | 0.78 | PREP (0.41) | PREPCA12CA1CA9MEN1 | |
| SCHEMBL25406124 | 0.76 | MEN1 (0.39) | MEN1KMT2ANPSR1MLYCDALDH1A1 | |
| SCHEMBL23491348 | 0.75 | PREP (0.57) | PREPCA12CA1CA9KMT2A | |
| SCHEMBL28510923 | 0.74 | PREP (0.44) | PREPCA12CA1CA9MEN1 | |
| SCHEMBL21807800 | 0.73 | — | — | |
| SCHEMBL6763899 | 0.73 | PREP (0.53) | PREPCA12CA1CA9ALDH1A1 | |
| SCHEMBL20364924 | 0.72 | PREP (0.55) | PREPCA12CA1CA9MEN1 | |
| SCHEMBL3751069 | 0.72 | BRD4 (0.55) | MEN1KMT2ANPSR1PTGS2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728240-B1 | ISOXAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2022-06-29 | — | — | EP | disclosed |
| EP-3986552-A1 | ISOXAZOLE CARBOXYLIC ACIDS AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2022-04-27 | — | — | EP | disclosed |
| EP-3986553-A1 | CYCLOBUTYL CARBOXYLIC ACIDS AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2022-04-27 | — | — | EP | disclosed |
| US-11180488-B2 | Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists | BRISTOL MYERS SQUIBB CO (US) | 2021-11-23 | — | — | US | disclosed |
| EP-3852746-A1 | CYCLOPENTYL ACIDS AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2021-07-28 | — | — | EP | disclosed |
| WO-2020257139-A1 | CYCLOBUTYL CARBOXYLIC ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2020257138-A1 | ISOXAZOLE CARBOXYLIC ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-12-24 | — | — | WO | disclosed |
| EP-3728240-A1 | ISOXAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2020-10-28 | — | — | EP | disclosed |
| US-20200317655-A1 | ISOXAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2020-10-08 | — | — | US | disclosed |
| WO-2020060915-A1 | CYCLOPENTYL ACIDS AS LPA ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2020-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200317655-A1 | ISOXAZOLE O-LINKED CARBAMOYL CYCLOHEXYL ACIDS AS LPA ANTAGONISTS | LPAR3, LPAR4, LPAR6 | PREP 2899/4885CA12 1468/4885CA1 773/4885 |
| US-11180488-B2 | Isoxazole o-linked carbamoyl cyclohexyl acids as LPA antagonists | LPAR3, LPAR6, LPAR4 | PREP 2830/4885CA12 1443/4885CA1 788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.